Arrowhead Pharma
(ARWR)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 09/30
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 264,033 | 256,472 | 27,767 | 542,709 | 2,500 |
| Gross Profit | 264,033 | 256,472 | 27,767 | 542,709 | 2,500 |
| Operating Expenses | 223,224 | 212,366 | 193,317 | 161,507 | 163,912 |
| Operating Income | 40,809 | 44,106 | -165,550 | 381,202 | -161,412 |
| Interest Expense | 22,505 | 21,694 | 24,382 | 21,639 | 21,646 |
| Other Income | 9,967 | 13,709 | 10,843 | 10,053 | 7,943 |
| Pre-tax Income | 28,271 | 36,121 | -179,089 | 369,616 | -175,115 |
| Income Tax | 29 | 20,000 | -437 | 1,753 | 103 |
| Net Income Continuous | 28,242 | 16,121 | -178,652 | 367,863 | -175,218 |
| Minority Interests | -2,569 | 39,871 | -3,411 | -2,582 | -2,133 |
| Net Income | $30,811 | $-23,750 | $-175,241 | $370,445 | $-173,085 |
| EPS Basic Total Ops | 0.22 | -0.14 | -1.26 | 2.78 | -1.39 |
| EPS Basic Continuous Ops | 0.21 | 0.16 | -1.28 | 2.76 | -1.40 |
| EPS Diluted Total Ops | 0.22 | -0.11 | -1.26 | 2.75 | -1.39 |
| EPS Diluted Continuous Ops | 0.20 | 0.18 | -1.28 | 2.74 | -1.40 |
| EPS Diluted Before Non-Recurring Items | N/A | -0.18 | -1.26 | 2.75 | -1.39 |
| EBITDA(a) | $47,199 | $49,248 | $-161,084 | $384,498 | $-156,177 |